On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...